Overview

• The composite dressing embeds miR-221-3p–loaded extracellular vesicles in a GelMA scaffold to downregulate thrombospondin-1 and overcome high-glucose angiogenesis inhibition.
• In diabetic mouse models, treated wounds achieved 90% closure within 12 days compared with significantly slower healing in untreated controls.
• Sustained release of engineered vesicles improved endothelial cell proliferation and migration at the wound site.
• The findings were published August 8 in Burns & Trauma and supported by grants from the Beijing Natural Science Foundation and the Independent Innovation Science Fund of The Fourth Medical Center of the PLA General Hospital.
• Researchers are expanding animal studies and preparing human clinical trials to validate safety, efficacy and explore use in other chronic wounds and tissue regeneration.